FR2421888A1
(fr)
*
|
1978-02-06 |
1979-11-02 |
Synthelabo |
Amides d'alkylene-diamines et leur application en therapeutique
|
JPS6016948B2
(ja)
*
|
1978-03-29 |
1985-04-30 |
住友化学工業株式会社 |
新規なキナゾリン誘導体及びその製造法
|
US4287341A
(en)
*
|
1979-11-01 |
1981-09-01 |
Pfizer Inc. |
Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
|
EP0022481A1
(fr)
*
|
1979-06-21 |
1981-01-21 |
Mitsubishi Yuka Pharmaceutical Co., Ltd. |
Dérivés de la 5,6-alcoylènepyrimidine, procédés pour leur préparation et préparations pharmaceutiques
|
US4377581A
(en)
*
|
1980-03-03 |
1983-03-22 |
Pfizer Inc. |
Chloro- and alkoxy-substituted-2,4-diaminoquinazolines
|
US4351940A
(en)
*
|
1980-03-03 |
1982-09-28 |
Pfizer Inc. |
Chloro- and alkoxy-substituted-2-chloro-4-aminodquinazolines
|
US4367335A
(en)
*
|
1981-08-03 |
1983-01-04 |
Mead Johnson & Company |
Thiazolidinylalkylene piperazine derivatives
|
DE3304292A1
(de)
*
|
1982-10-11 |
1984-04-12 |
Brown, Boveri & Cie Ag, 6800 Mannheim |
Verfahren und vorrichtung zum ausregeln von netzfrequenzeinbruechen bei einem gleitdruckbetriebenen dampfkraftwerkblock
|
DE3346675A1
(de)
*
|
1983-12-23 |
1985-07-04 |
Beiersdorf Ag, 2000 Hamburg |
Substituierte 1-(4-amino-6,7-dialkoxy-chinazolinyl)-4- cyclohexenyl-derivate des piperazins und homopiperazins, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen und zwischenprodukte
|
AT384218B
(de)
*
|
1985-12-04 |
1987-10-12 |
Gerot Pharmazeutika |
Verfahren zur herstellung von neuen chinazolin-derivaten
|
JP2657760B2
(ja)
*
|
1992-07-15 |
1997-09-24 |
小野薬品工業株式会社 |
4−アミノキナゾリン誘導体およびそれを含有する医薬品
|
CA2077252C
(fr)
*
|
1992-08-31 |
2001-04-10 |
Khashayar Karimian |
Methodes de fabrication d'urees et de guanidines et composes intermediaires servant a ces syntheses
|
US20060222647A1
(en)
*
|
1993-05-27 |
2006-10-05 |
Beavo Joseph A |
Methods and compositions for modulating the activity of PDE5
|
US5696159A
(en)
*
|
1994-08-03 |
1997-12-09 |
Cell Pathways, Inc. |
Lactone compounds for treating patients with precancerous lesions
|
US5776962A
(en)
*
|
1994-08-03 |
1998-07-07 |
Cell Pathways, Inc. |
Lactone compounds for treating patient with precancerous lesions
|
US5869486A
(en)
*
|
1995-02-24 |
1999-02-09 |
Ono Pharmaceutical Co., Ltd. |
Fused pyrimidines and pyriazines as pharmaceutical compounds
|
US6200980B1
(en)
|
1995-06-07 |
2001-03-13 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl purinone derivatives
|
US6060477A
(en)
*
|
1995-06-07 |
2000-05-09 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
|
US6232312B1
(en)
|
1995-06-07 |
2001-05-15 |
Cell Pathways, Inc. |
Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
|
US5874440A
(en)
*
|
1995-06-07 |
1999-02-23 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
|
US6046216A
(en)
*
|
1995-06-07 |
2000-04-04 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
|
US6046206A
(en)
*
|
1995-06-07 |
2000-04-04 |
Cell Pathways, Inc. |
Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
|
US6262059B1
(en)
|
1995-06-07 |
2001-07-17 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with quinazoline derivatives
|
US20050065161A1
(en)
*
|
1996-02-02 |
2005-03-24 |
Nitromed, Inc. |
Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
|
US20020143007A1
(en)
*
|
1996-02-02 |
2002-10-03 |
Garvey David S. |
Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
|
US5932538A
(en)
*
|
1996-02-02 |
1999-08-03 |
Nitromed, Inc. |
Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
|
GB9708917D0
(en)
*
|
1997-05-01 |
1997-06-25 |
Pfizer Ltd |
Compounds useful in therapy
|
US5858694A
(en)
*
|
1997-05-30 |
1999-01-12 |
Cell Pathways, Inc. |
Method for identifying compounds for inhibition of cancerous lesions
|
CA2238283C
(fr)
*
|
1997-05-30 |
2002-08-20 |
Cell Pathways, Inc. |
Methode d'identification de composes visant a inhiber les lesions neoplasiques, compositions pharmaceutiques a prtir de ces composes et compositions pour traiter les lesions neoplasiques
|
ID25871A
(id)
|
1997-11-12 |
2000-11-09 |
Bayer Ag |
Imidazotriazinon tersubstitusi-2-fenil
|
US5852035A
(en)
*
|
1997-12-12 |
1998-12-22 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
|
US6410584B1
(en)
*
|
1998-01-14 |
2002-06-25 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells with indole derivatives
|
US6046199A
(en)
*
|
1998-01-14 |
2000-04-04 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
|
US5942520A
(en)
*
|
1998-01-27 |
1999-08-24 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
|
US5990117A
(en)
*
|
1998-04-15 |
1999-11-23 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
|
US6180629B1
(en)
|
1998-08-14 |
2001-01-30 |
Cell Pathways, Inc. |
[4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
|
US6124303A
(en)
*
|
1998-09-11 |
2000-09-26 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
|
US6268372B1
(en)
|
1998-09-11 |
2001-07-31 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
|
US6200771B1
(en)
|
1998-10-15 |
2001-03-13 |
Cell Pathways, Inc. |
Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
|
US6130053A
(en)
*
|
1999-08-03 |
2000-10-10 |
Cell Pathways, Inc. |
Method for selecting compounds for inhibition of neoplastic lesions
|
US6133271A
(en)
*
|
1998-11-19 |
2000-10-17 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
|
US6187779B1
(en)
|
1998-11-20 |
2001-02-13 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
|
US6369092B1
(en)
|
1998-11-23 |
2002-04-09 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted benzimidazole derivatives
|
US6486155B1
(en)
|
1998-11-24 |
2002-11-26 |
Cell Pathways Inc |
Method of inhibiting neoplastic cells with isoquinoline derivatives
|
US6077842A
(en)
*
|
1998-11-24 |
2000-06-20 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
|
US6034099A
(en)
*
|
1998-11-24 |
2000-03-07 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
|
US6025394A
(en)
|
1999-01-29 |
2000-02-15 |
Cell Pathways, Inc. |
Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
|
US6020379A
(en)
*
|
1999-02-19 |
2000-02-01 |
Cell Pathways, Inc. |
Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
|
US6555547B1
(en)
|
2000-02-28 |
2003-04-29 |
Cell Pathways, Inc. |
Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
|
US6569638B1
(en)
|
2000-03-03 |
2003-05-27 |
Cell Pathways, Inc |
Method for screening compounds for the treatment of neoplasia
|
MXPA03007623A
(es)
*
|
2001-02-26 |
2003-12-04 |
Tanabe Seiyaku Co |
Derivado de piridopirimidina o naftiridina.
|
JP4540295B2
(ja)
*
|
2001-05-09 |
2010-09-08 |
バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト |
2−フェニル置換イミダゾトリアジノンの新しい用途
|
EP1312363A1
(fr)
*
|
2001-09-28 |
2003-05-21 |
Pfizer Products Inc. |
Méthode de traitement et kit comprenant un secrétagogue d'hormone de croissance
|
US7342884B2
(en)
*
|
2002-03-13 |
2008-03-11 |
Harmonic, Inc. |
Method and apparatus for one directional communications in bidirectional communications channel
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
US7208516B2
(en)
*
|
2002-03-20 |
2007-04-24 |
Celgene Corporation |
Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
US7276529B2
(en)
*
|
2002-03-20 |
2007-10-02 |
Celgene Corporation |
Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
EP1538913A2
(fr)
*
|
2002-04-12 |
2005-06-15 |
Celgene Corporation |
Modulation de differenciation de cellule souche et de cellule progenitrice, analyses et utilisations associees
|
EP1496878A4
(fr)
*
|
2002-04-12 |
2007-12-26 |
Celgene Corp |
Techniques d'identification de modulateurs d'angiogenese, composes decouverts par ces techniques et techniques de traitement utilisant ces composes
|
DE10232113A1
(de)
|
2002-07-16 |
2004-01-29 |
Bayer Ag |
Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
|
RU2006121990A
(ru)
*
|
2003-11-21 |
2007-12-27 |
Эррэй Биофарма Инк. (Us) |
Ингибиторы протеинкиназ акт
|
DE102005001989A1
(de)
*
|
2005-01-15 |
2006-07-20 |
Bayer Healthcare Ag |
Intravenöse Formulierungen von PDE-Inhibitoren
|
DE102005009240A1
(de)
*
|
2005-03-01 |
2006-09-07 |
Bayer Healthcare Ag |
Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
|
DE102005009241A1
(de)
*
|
2005-03-01 |
2006-09-07 |
Bayer Healthcare Ag |
Arzneiformen mit kontrollierter Bioverfügbarkeit
|
JP2009509984A
(ja)
*
|
2005-09-29 |
2009-03-12 |
バイエル・ヘルスケア・アクチェンゲゼルシャフト |
泌尿器系障害の処置用のpde阻害剤およびそれらの組合せ
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
DE602007011628D1
(de)
|
2006-07-06 |
2011-02-10 |
Array Biopharma Inc |
Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
|
PL2049500T3
(pl)
*
|
2006-07-06 |
2012-02-29 |
Array Biopharma Inc |
Cyklopenta[d]pirymidyny jako inhibitory kinaz białkowych AKT
|
US8063050B2
(en)
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
ATE532789T1
(de)
|
2006-07-06 |
2011-11-15 |
Array Biopharma Inc |
Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
|
WO2008151734A1
(fr)
*
|
2007-06-13 |
2008-12-18 |
Bayer Schering Pharma Aktiengesellschaft |
Inhibiteurs de la phosphodiestérase (pde) destinés au traitement des troubles de l'audition
|
US8377937B2
(en)
*
|
2007-07-05 |
2013-02-19 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
US9409886B2
(en)
|
2007-07-05 |
2016-08-09 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
CN103396409B
(zh)
|
2007-07-05 |
2015-03-11 |
阵列生物制药公司 |
作为akt蛋白激酶抑制剂的嘧啶基环戊烷
|
US8846683B2
(en)
|
2007-07-05 |
2014-09-30 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
US8835434B2
(en)
*
|
2008-01-09 |
2014-09-16 |
Array Biopharma, Inc. |
Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
|
US8853216B2
(en)
*
|
2008-01-09 |
2014-10-07 |
Array Biopharma, Inc. |
Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
|
CA2718412A1
(fr)
*
|
2008-03-24 |
2009-10-01 |
Celgene Corporation |
Traitement du psoriasis ou du rhumatisme psoriasique par le cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
|
BR112013025353A8
(pt)
|
2011-04-01 |
2018-01-02 |
Genentech Inc |
combinação de a) um composto de fórmula ia, composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, método para tratamento de um distúrbio hiperproliferativo em um mamífero, uso de um composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, kit e produto
|
JP6147246B2
(ja)
|
2011-04-01 |
2017-06-14 |
ジェネンテック, インコーポレイテッド |
Akt及びmek阻害剤化合物の組み合わせ、及び使用方法
|
ES2749433T3
(es)
|
2014-06-23 |
2020-03-20 |
Celgene Corp |
Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
|
WO2019010180A1
(fr)
*
|
2017-07-06 |
2019-01-10 |
Case Western Reserve University |
Agonistes peptidiques et à petites molécules d'epha et leurs utilisations
|